Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

EJHaem

Showing results (371-380 of 930) with videos related to

Pageof 93
Sort By:
Ejhaem|July 18, 2022
Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case reportManar Alabdulbaqi, Melissa Toupin, Philip Berardi, et al.
Ejhaem|July 18, 2022
Immune reconstitution in children following chemotherapy for acute leukemiaAnthony P Williams, Jessica Bate, Rachael Brooks, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Ejhaem|July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutationBaptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Ejhaem|May 19, 2023
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemiaIan M Bouligny, Graeme Murray, Michael Doyel, et al.
Ejhaem|May 19, 2023
Red blood cell alloantibodies in paediatric transfusion in sub-Saharan Africa: A new cohort and literature reviewMacoura Gadji, Guéda Cobar, Alioune Thiongane, et al.
Ejhaem|May 19, 2023
Community-level socioeconomic distress is associated with nutritional status in adults with sickle cell anemiaSyeda Akila Ally, Jin Han, Ryan Sun, et al.
Ejhaem|May 19, 2023
Erythroleukemia: ClassificationNathalie Cervera, Arnaud Guille, José Adélaïde, et al.
Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Pageof 93

Showing results (371-380 of 930) with videos related to

Sort By:
Pageof 93
Ejhaem|July 18, 2022
Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case reportManar Alabdulbaqi, Melissa Toupin, Philip Berardi, et al.
Ejhaem|July 18, 2022
Immune reconstitution in children following chemotherapy for acute leukemiaAnthony P Williams, Jessica Bate, Rachael Brooks, et al.
Ejhaem|July 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trialElizabeth H Phillips, Catherine Burton, Amy A Kirkwood, et al.
Ejhaem|July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutationBaptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Ejhaem|May 19, 2023
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemiaIan M Bouligny, Graeme Murray, Michael Doyel, et al.
Ejhaem|May 19, 2023
Red blood cell alloantibodies in paediatric transfusion in sub-Saharan Africa: A new cohort and literature reviewMacoura Gadji, Guéda Cobar, Alioune Thiongane, et al.
Ejhaem|May 19, 2023
Community-level socioeconomic distress is associated with nutritional status in adults with sickle cell anemiaSyeda Akila Ally, Jin Han, Ryan Sun, et al.
Ejhaem|May 19, 2023
Erythroleukemia: ClassificationNathalie Cervera, Arnaud Guille, José Adélaïde, et al.
Ejhaem|May 19, 2023
A phase 1 first-in-human study of GS-0189, an anti-signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)Mayur Narkhede, Nancy L Bartlett, Sami Ibrahimi, et al.
Ejhaem|May 19, 2023
Variability of definition of high-risk multiple myeloma across phase III clinical trialsFaris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, et al.
Pageof 93